|
Synta Trial Should Continue, Data Monitoring Committee Says
After reviewing safety data of Synta Pharmaceuticals’ Phase III trial of elesclomol in metastatic melanoma, an independent data monitoring committee recommended the trial continue.
The blind, randomized, controlled study trial is enrolling 630 patients with stage IV metastatic melanoma who have not received prior chemotherapy but who may have been treated with nonchemotherapeutic agents. It will be conducted at 150 centers worldwide, Synta said. Elesclomol is an oxidative stress inducer that triggers programmed cell death in cancer cells. It is developed under a global collaboration agreement between Synta Pharmaceuticals and GlaxoSmithKline. |
Register Now
Archives